Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Novel multi target-directed ligands targeting 5-HT4 receptors with in cellulo antioxidant properties as promising leads in Alzheimer's disease.

Lanthier C, Payan H, Liparulo I, Hatat B, Lecoutey C, Since M, Davis A, Bergamini C, Claeysen S, Dallemagne P, Bolognesi ML, Rochais C.

Eur J Med Chem. 2019 Aug 6;182:111596. doi: 10.1016/j.ejmech.2019.111596. [Epub ahead of print]

PMID:
31419776
2.

Benzothienoquinazolinones as new multi-target scaffolds: Dual inhibition of human Topoisomerase I and tubulin polymerization.

Ceramella J, Caruso A, Occhiuzzi MA, Iacopetta D, Barbarossa A, Rizzuti B, Dallemagne P, Rault S, El-Kashef H, Saturnino C, Grande F, Sinicropi MS.

Eur J Med Chem. 2019 Aug 2;181:111583. doi: 10.1016/j.ejmech.2019.111583. [Epub ahead of print]

PMID:
31400710
3.

Inhibiting Acetylcholinesterase to Activate Pleiotropic Prodrugs with Therapeutic Interest in Alzheimer's Disease.

Toublet FX, Lecoutey C, Lalut J, Hatat B, Davis A, Since M, Corvaisier S, Freret T, Sopkova de Oliveira Santos J, Claeysen S, Boulouard M, Dallemagne P, Rochais C.

Molecules. 2019 Jul 31;24(15). pii: E2786. doi: 10.3390/molecules24152786.

4.
5.

26th Annual GP2A Medicinal Chemistry Conference & 32nd Journées Franco-Belges de Pharmacochimie.

Dallemagne P, Rochais C, Marchand P, Besson T.

Pharmaceuticals (Basel). 2019 May 16;12(2). pii: E73. doi: 10.3390/ph12020073.

6.

A chemical screen identifies two novel small compounds that alter Arabidopsis thaliana pollen tube growth.

Laggoun F, Dardelle F, Dehors J, Falconet D, Driouich A, Rochais C, Dallemagne P, Lehner A, Mollet JC.

BMC Plant Biol. 2019 Apr 22;19(1):152. doi: 10.1186/s12870-019-1743-9.

7.

New piperazine multi-effect drugs prevent neurofibrillary degeneration and amyloid deposition, and preserve memory in animal models of Alzheimer's disease.

Sergeant N, Vingtdeux V, Eddarkaoui S, Gay M, Evrard C, Le Fur N, Laurent C, Caillierez R, Obriot H, Larchanché PE, Farce A, Coevoet M, Carato P, Kouach M, Descat A, Dallemagne P, Buée-Scherrer V, Blum D, Hamdane M, Buée L, Melnyk P.

Neurobiol Dis. 2019 Sep;129:217-233. doi: 10.1016/j.nbd.2019.03.028. Epub 2019 Mar 27.

PMID:
30928644
8.

Novel multitarget-directed ligands targeting acetylcholinesterase and σ1 receptors as lead compounds for treatment of Alzheimer's disease: Synthesis, evaluation, and structural characterization of their complexes with acetylcholinesterase.

Lalut J, Santoni G, Karila D, Lecoutey C, Davis A, Nachon F, Silman I, Sussman J, Weik M, Maurice T, Dallemagne P, Rochais C.

Eur J Med Chem. 2019 Jan 15;162:234-248. doi: 10.1016/j.ejmech.2018.10.064. Epub 2018 Nov 8.

PMID:
30447434
9.

Screening and evaluation of antiviral compounds against Equid alpha-herpesviruses using an impedance-based cellular assay.

Thieulent CJ, Hue ES, Fortier CI, Dallemagne P, Zientara S, Munier-Lehmann H, Hans A, Fortier GD, Pitel PH, Vidalain PO, Pronost SL.

Virology. 2019 Jan 2;526:105-116. doi: 10.1016/j.virol.2018.10.013. Epub 2018 Oct 26.

PMID:
30388626
10.

The 52nd International Conference on Medicinal Chemistry (RICT 2016) of the French Medicinal Chemistry Society (SCT) Held in Caen (Normandy).

Sapi J, Van Hijfte L, Dallemagne P.

ChemMedChem. 2017 Jun 21;12(12):862-871. doi: 10.1002/cmdc.201700336.

PMID:
28636129
11.

Modulating 5-HT4 and 5-HT6 receptors in Alzheimer's disease treatment.

Lalut J, Karila D, Dallemagne P, Rochais C.

Future Med Chem. 2017 May;9(8):781-795. doi: 10.4155/fmc-2017-0031. Epub 2017 May 15. Review.

PMID:
28504917
12.

Benzylphenylpyrrolizinones with Anti-amyloid and Radical Scavenging Effects, Potentially Useful in Alzheimer's Disease Treatment.

Jourdan JP, Since M, El Kihel L, Lecoutey C, Corvaisier S, Legay R, Sopková-de Oliveira Santos J, Cresteil T, Malzert-Fréon A, Rochais C, Dallemagne P.

ChemMedChem. 2017 Jun 21;12(12):913-916. doi: 10.1002/cmdc.201700102. Epub 2017 Apr 12.

PMID:
28342294
13.

Multifaceted properties of 1,4-dimethylcarbazoles: Focus on trimethoxybenzamide and trimethoxyphenylurea derivatives as novel human topoisomerase II inhibitors.

Iacopetta D, Rosano C, Puoci F, Parisi OI, Saturnino C, Caruso A, Longo P, Ceramella J, Malzert-Fréon A, Dallemagne P, Rault S, Sinicropi MS.

Eur J Pharm Sci. 2017 Jan 1;96:263-272. doi: 10.1016/j.ejps.2016.09.039. Epub 2016 Oct 1.

PMID:
27702608
14.

Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer's disease.

Yahiaoui S, Hamidouche K, Ballandonne C, Davis A, de Oliveira Santos JS, Freret T, Boulouard M, Rochais C, Dallemagne P.

Eur J Med Chem. 2016 Oct 4;121:283-293. doi: 10.1016/j.ejmech.2016.05.048. Epub 2016 May 26.

PMID:
27266998
15.

Synthesis and evaluation of novel serotonin 4 receptor radiotracers for single photon emission computed tomography.

Lalut J, Tournier BB, Cailly T, Lecoutey C, Corvaisier S, Davis A, Ballandonne C, Since M, Millet P, Fabis F, Dallemagne P, Rochais C.

Eur J Med Chem. 2016 Jun 30;116:90-101. doi: 10.1016/j.ejmech.2016.03.059. Epub 2016 Mar 25.

PMID:
27060761
16.

Novel benzylidenephenylpyrrolizinones with pleiotropic activities potentially useful in Alzheimer's disease treatment.

Jourdan JP, Since M, El Kihel L, Lecoutey C, Corvaisier S, Legay R, Sopkova-de Oliveira Santos J, Cresteil T, Malzert-Fréon A, Rochais C, Dallemagne P.

Eur J Med Chem. 2016 May 23;114:365-79. doi: 10.1016/j.ejmech.2016.03.023. Epub 2016 Mar 12.

PMID:
27046230
17.

3-(Dipropylamino)-5-hydroxybenzofuro[2,3-f]quinazolin-1(2H)-one (DPA-HBFQ-1) plays an inhibitory role on breast cancer cell growth and progression.

Rizza P, Pellegrino M, Caruso A, Iacopetta D, Sinicropi MS, Rault S, Lancelot JC, El-Kashef H, Lesnard A, Rochais C, Dallemagne P, Saturnino C, Giordano F, Catalano S, Andò S.

Eur J Med Chem. 2016 Jan 1;107:275-87. doi: 10.1016/j.ejmech.2015.11.004. Epub 2015 Nov 10.

PMID:
26599533
18.

Chronic activation of 5-HT4 receptors or blockade of 5-HT6 receptors improve memory performances.

Quiedeville A, Boulouard M, Hamidouche K, Da Silva Costa-Aze V, Nee G, Rochais C, Dallemagne P, Fabis F, Freret T, Bouet V.

Behav Brain Res. 2015 Oct 15;293:10-7. doi: 10.1016/j.bbr.2015.07.020. Epub 2015 Jul 14.

PMID:
26187692
19.

Therapeutic Potential of 5-HT6 Receptor Agonists.

Karila D, Freret T, Bouet V, Boulouard M, Dallemagne P, Rochais C.

J Med Chem. 2015 Oct 22;58(20):7901-12. doi: 10.1021/acs.jmedchem.5b00179. Epub 2015 Jul 2. Review.

PMID:
26099069
20.

Recent Advances in Phenanthroindolizidine and Phenanthroquinolizidine Derivatives with Anticancer Activities.

de Fatima Pereira M, Rochais C, Dallemagne P.

Anticancer Agents Med Chem. 2015;15(9):1080-91. Review.

PMID:
25991426
21.

Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride.

Rochais C, Lecoutey C, Gaven F, Giannoni P, Hamidouche K, Hedou D, Dubost E, Genest D, Yahiaoui S, Freret T, Bouet V, Dauphin F, Sopkova de Oliveira Santos J, Ballandonne C, Corvaisier S, Malzert-Fréon A, Legay R, Boulouard M, Claeysen S, Dallemagne P.

J Med Chem. 2015 Apr 9;58(7):3172-87. doi: 10.1021/acs.jmedchem.5b00115. Epub 2015 Mar 31.

PMID:
25793650
22.

Discovery of new thienopyrimidinone derivatives displaying antimalarial properties toward both erythrocytic and hepatic stages of Plasmodium.

Cohen A, Suzanne P, Lancelot JC, Verhaeghe P, Lesnard A, Basmaciyan L, Hutter S, Laget M, Dumètre A, Paloque L, Deharo E, Crozet MD, Rathelot P, Dallemagne P, Lorthiois A, Sibley CH, Vanelle P, Valentin A, Mazier D, Rault S, Azas N.

Eur J Med Chem. 2015 May 5;95:16-28. doi: 10.1016/j.ejmech.2015.03.011. Epub 2015 Mar 10.

PMID:
25791675
23.

6-Sulfonylbenzothiazolones as potential scaffolds for the design of 5-HT6 ligands.

Larchanche PE, Ultré V, Le Broc D, Ballandone C, Furman C, Dallemagne P, Melnyk P, Carato P.

Eur J Med Chem. 2015 Mar 6;92:807-17. doi: 10.1016/j.ejmech.2015.01.052. Epub 2015 Jan 26.

PMID:
25637882
24.

Indenopyrazole oxime ethers: synthesis and β1-adrenergic blocking activity.

Angelone T, Caruso A, Rochais C, Caputo AM, Cerra MC, Dallemagne P, Filice E, Genest D, Pasqua T, Puoci F, Saturnino C, Sinicropi MS, El-Kashef H.

Eur J Med Chem. 2015 Mar 6;92:672-81. doi: 10.1016/j.ejmech.2015.01.037. Epub 2015 Jan 20.

PMID:
25618014
25.

Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment.

Lecoutey C, Hedou D, Freret T, Giannoni P, Gaven F, Since M, Bouet V, Ballandonne C, Corvaisier S, Malzert Fréon A, Mignani S, Cresteil T, Boulouard M, Claeysen S, Rochais C, Dallemagne P.

Proc Natl Acad Sci U S A. 2014 Sep 9;111(36):E3825-30. doi: 10.1073/pnas.1410315111. Epub 2014 Aug 25.

26.

Synthesis and in vitro evaluation of 4-trichloromethylpyrrolo[1,2-a]quinoxalines as new antiplasmodial agents.

Primas N, Suzanne P, Verhaeghe P, Hutter S, Kieffer C, Laget M, Cohen A, Broggi J, Lancelot JC, Lesnard A, Dallemagne P, Rathelot P, Rault S, Vanelle P, Azas N.

Eur J Med Chem. 2014 Aug 18;83:26-35. doi: 10.1016/j.ejmech.2014.06.014. Epub 2014 Jun 10.

PMID:
24946216
27.

Synthesis and evaluation of cytotoxic activities of new guanidines derived from carbazoles.

Caruso A, Sinicropi MS, Lancelot JC, El-Kashef H, Saturnino C, Aubert G, Ballandonne C, Lesnard A, Cresteil T, Dallemagne P, Rault S.

Bioorg Med Chem Lett. 2014 Jan 15;24(2):467-72. doi: 10.1016/j.bmcl.2013.12.047. Epub 2013 Dec 17.

PMID:
24374274
28.

N-substituted piperazinopyridylsteroid derivatives as abiraterone analogues inhibit growth and induce pro-apoptosis in human hormone-independent prostate cancer cell lines.

Brossard D, Zhang Y, Haider SM, Sgobba M, Khalid M, Legay R, Duterque-Coquillaud M, Galera P, Rault S, Dallemagne P, Moslemi S, El Kihel L.

Chem Biol Drug Des. 2013 Nov;82(5):620-9. doi: 10.1111/cbdd.12195.

PMID:
23906044
29.

MR22388, a novel anti-cancer agent with a strong FLT-3 ITD kinase affinity.

Rochais C, Cresteil T, Perri V, Jouanne M, Lesnard A, Rault S, Dallemagne P.

Cancer Lett. 2013 Apr 30;331(1):92-8. doi: 10.1016/j.canlet.2012.12.017. Epub 2012 Dec 23.

PMID:
23268332
30.

Synthesis of novel 7-oxo and 7-hydroxy trifluoroallocolchicinoids with cytotoxic effect.

Chosson E, Santoro F, Rochais C, Santos JS, Legay R, Thoret S, Cresteil T, Sinicropi MS, Besson T, Dallemagne P.

Bioorg Med Chem. 2012 Apr 15;20(8):2614-23. doi: 10.1016/j.bmc.2012.02.043. Epub 2012 Mar 3.

PMID:
22429510
31.

Synergistic effect of acetylcholinesterase inhibition (donepezil) and 5-HT(4) receptor activation (RS67333) on object recognition in mice.

Freret T, Bouet V, Quiedeville A, Nee G, Dallemagne P, Rochais C, Boulouard M.

Behav Brain Res. 2012 Apr 21;230(1):304-8. doi: 10.1016/j.bbr.2012.02.012. Epub 2012 Feb 14.

PMID:
22348892
33.

Virtual screening discovery of new acetylcholinesterase inhibitors issued from CERMN chemical library.

Sopkova-de Oliveira Santos J, Lesnard A, Agondanou JH, Dupont N, Godard AM, Stiebing S, Rochais C, Fabis F, Dallemagne P, Bureau R, Rault S.

J Chem Inf Model. 2010 Mar 22;50(3):422-8. doi: 10.1021/ci900491t.

PMID:
20196555
34.

Hydrogenative desulphurization of thienopyrrolizinones: an easy and selective access to (Z)-phenethylidenepyrrolizinones with in vitro cytotoxic activity.

Perri V, Rochais C, Sopkova-de Oliveira Santos J, Legay R, Cresteil T, Dallemagne P, Rault S.

Eur J Med Chem. 2010 Mar;45(3):1146-50. doi: 10.1016/j.ejmech.2009.12.021. Epub 2009 Dec 21.

PMID:
20053482
35.

Synthesis, reactivity and biological evaluation of novel halogenated tripentones.

Perri V, Rochais C, Cresteil T, Dallemagne P, Rault S.

Bioorg Med Chem. 2009 Nov 15;17(22):7783-8. doi: 10.1016/j.bmc.2009.09.027. Epub 2009 Sep 19.

PMID:
19822434
36.

Tripentones: a promising series of potent anti-cancer agents.

Rochais C, Dallemagne P, Rault S.

Anticancer Agents Med Chem. 2009 May;9(4):369-80. Review.

PMID:
19442038
37.

Synthesis and biological evaluation of new donepezil-like Thiaindanones as AChE inhibitors.

Omran Z, Stiebing S, Godard AM, Sopkova-De Oliveira-Santos J, Dallemagne P.

J Enzyme Inhib Med Chem. 2008 Oct;23(5):696-703. doi: 10.1080/14756360802208053 .

PMID:
18821258
38.

Synthesis of new dipyrrolo- and furopyrrolopyrazinones related to tripentones and their biological evaluation as potential kinases (CDKs1-5, GSK-3) inhibitors.

Rochais C, Duc NV, Lescot E, Sopkova-de Oliveira Santos J, Bureau R, Meijer L, Dallemagne P, Rault S.

Eur J Med Chem. 2009 Feb;44(2):708-16. doi: 10.1016/j.ejmech.2008.05.011. Epub 2008 May 23.

PMID:
18586356
39.

Synthesis of new bisaryl cyclopentathiophene and thienocyclopentoxazolidine derivatives as potential cytotoxic agents.

Omran Z, Dallemagne P, Rault S.

J Enzyme Inhib Med Chem. 2007 Oct;22(5):632-7.

PMID:
18035831
40.

Synthesis of new 4-[2-(alkylamino) ethylthio]pyrrolo[1,2-a]quinoxaline and 5-[2-(alkylamino) ethylthio]pyrrolo[1,2-a]thieno[3,2-e]pyrazine derivatives, as potential bacterial multidrug resistance pump inhibitors.

Vidaillac C, Guillon J, Moreau S, Arpin C, Lagardère A, Larrouture S, Dallemagne P, Caignard DH, Quentin C, Jarry C.

J Enzyme Inhib Med Chem. 2007 Oct;22(5):620-31.

PMID:
18035830
41.

Synthesis and biological evaluation of novel pyrrolopyrrolizinones as anticancer agents.

Rochais C, Lisowski V, Dallemagne P, Rault S.

Bioorg Med Chem. 2006 Dec 15;14(24):8162-75. Epub 2006 Sep 29.

PMID:
17011196
42.
43.

Synthesis and biological evaluation as AChE inhibitors of new indanones and thiaindanones related to donepezil.

Omran Z, Cailly T, Lescot E, Santos JS, Agondanou JH, Lisowski V, Fabis F, Godard AM, Stiebing S, Le Flem G, Boulouard M, Dauphin F, Dallemagne P, Rault S.

Eur J Med Chem. 2005 Dec;40(12):1222-45. Epub 2005 Aug 30.

PMID:
16137794
44.

[Study of in vitro cytotoxic activity of cyclopentanones derivatives].

Ben Sassi A, Tabka T, Gauduchon P, Dallemagne P, Aouni M.

Tunis Med. 2004 Oct;82(10):919-26. French.

PMID:
15686188
45.

Synthesis and biological evaluation of thienopyrrolizines, a new family of CDK/GSK-3 inhibitors.

Rochais C, Lescot E, Lisowski V, Lepailleur A, Santos JS, Bureau R, Dallemagne P, Meijer L, Rault S.

J Enzyme Inhib Med Chem. 2004 Dec;19(6):585-93.

PMID:
15662962
46.

Synthesis and preliminary in vitro evaluation of antimycobacterial activity of new pyrrolo[1,2-a] quinoxaline-carboxylic acid hydrazide derivatives.

Guillon J, Reynolds RC, Leger JM, Guie MA, Massip S, Dallemagne P, Jarry C.

J Enzyme Inhib Med Chem. 2004 Dec;19(6):489-95.

PMID:
15662953
47.

Synthesis, antimalarial activity, and molecular modeling of new pyrrolo[1,2-a]quinoxalines, bispyrrolo[1,2-a]quinoxalines, bispyrido[3,2-e]pyrrolo[1,2-a]pyrazines, and bispyrrolo[1,2-a]thieno[3,2-e]pyrazines.

Guillon J, Grellier P, Labaied M, Sonnet P, Léger JM, Déprez-Poulain R, Forfar-Bares I, Dallemagne P, Lemaître N, Péhourcq F, Rochette J, Sergheraert C, Jarry C.

J Med Chem. 2004 Apr 8;47(8):1997-2009.

PMID:
15055999
48.

Synthesis and initial results for MAO-B inhibition by new N-propargyl-3-pyrrol-1-ylindanamine derivatives, analogues of rasagiline.

Guillon J, Hébert G, Dallemagne P, Léger JM, Vidaillac C, Thé C, Lisowski V, Rault S, Demotes-Mainard J, Jarry C.

J Enzyme Inhib Med Chem. 2003 Apr;18(2):147-53.

PMID:
12943198
49.

A first cyclopenta[c]thiophene dimer as a new bivalent potent cytotoxic derivative.

Khanh LP, Dallemagne P, Landelle H, Rault S.

J Enzyme Inhib Med Chem. 2002 Dec;17(6):439-42.

PMID:
12683681
50.

Synthesis and biological evaluation of five-membered heterocycles fused to cyclopenta[c]thiophene as new antitumor agents.

Dallemagne P, Khanh LP, Alsaïdi A, Varlet I, Collot V, Paillet M, Bureau R, Rault S.

Bioorg Med Chem. 2003 Apr 3;11(7):1161-7.

PMID:
12628643

Supplemental Content

Loading ...
Support Center